AMP Starts New Positions in two Companies NewLink Genetics and Lipocine Inc. and Adds to Clearside


This past week AMP added new positions in its Hypothetical Fund by purchasing $50K and $25K worth of shares in NewLink Genetics (NLNK: $12.75/share) and Lipocine Inc (LPCN: $3.56/share) respectively.

NewLink Genetics commercializes novel immuno-oncology products and Lipocine is using proprietary drug delivery technologies for men's and women's health with two assets as oral testosterone replacements and one for recurrent preterm birth.

Additionally, AMP purchased 1,691 shares of CLSD at $7.39/share to bring its invested position up to $50K.


*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon